

1 Maternal smoking DNA methylation risk score associated with health
2 outcomes in offspring of European and South Asian ancestry

3
4 Wei Q. Deng^{1,2,3*}, Nathan Cawte⁴, Natalie Campbell³, Sandi M. Azab^{3,5}, Russell J de Souza^{3,5},
5 Amel Lamri^{3,4}, Katherine M. Morrison⁶, Stephanie A. Atkinson⁶, Padmaja Subbarao⁷, Stuart E.
6 Turvey⁸, Theo J. Moraes^{7,9}, Koon K. Teo^{3,4,5}, Piush Mandhane¹⁰, Meghan B. Azad¹¹, Elinor
7 Simons¹², Guillaume Pare^{4,5,13,14}, Sonia S. Anand^{3,4,5*}

- 8
9
10 1. Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, Hamilton,
11 Canada.
12 2. Department of Psychiatry and Behavioural Neurosciences, McMaster University,
13 Hamilton, Canada.
14 3. Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton,
15 Canada.
16 4. Population Health Research Institute, David Braley Cardiac, Vascular and Stroke
17 Research Institute, Hamilton, Canada.
18 5. Department of Health Research Methods, Evidence, and Impact, McMaster University,
19 Hamilton, Canada.
20 6. Department of Pediatrics, McMaster University, Hamilton, Canada.
21 7. Department of Pediatrics, University of Toronto, Toronto, Canada.
22 8. Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
23 Vancouver, Canada

- 24 9. Program in Translational Medicine, SickKids Research Institute, Toronto, Canada
- 25 10. Department of Pediatrics, University of Alberta, Edmonton, Canada
- 26 11. Children’s Hospital Research Institute of Manitoba, Department of Pediatrics and Child
- 27 Health, University of Manitoba, Winnipeg, Canada
- 28 12. Section of Allergy and Immunology, Department of Pediatrics and Child Health,
- 29 University of Manitoba, Canada
- 30 13. Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and
- 31 Stroke Research Institute, Hamilton, Canada
- 32 14. Department of Pathology and Molecular Medicine, McMaster University, Michael G.
- 33 DeGroote School of Medicine, Hamilton, Canada

34

35 *Correspondence: dengwq@mcmaster.ca; anands@mcmaster.ca

36

37

38

39

40

41

42

43

44

45

46 **Abstract**

47 Maternal smoking has been linked to adverse health outcomes in newborns but the extent to
48 which it impacts newborn health has not been quantified through an aggregated cord blood DNA
49 methylation (DNAm) score. Here we propose the first cord blood DNAm score to capture the
50 epigenetic signature of maternal smoking. We first examined the association between individual
51 CpGs and cigarette smoking during pregnancy in two White European birth cohorts (n = 763),
52 and smoking exposure in the White European and the South Asian birth cohorts (n = 887).
53 Several previously reported genes for maternal smoking were supported, with the strongest and
54 most consistent signal from the *GFII* gene ($p < 5 \times 10^{-5}$). Leveraging previously reported CpGs
55 for maternal smoking, we constructed a cord blood epigenetic score of maternal smoking that
56 was internally validated in one of the European-origin cohorts. This score was then tested for
57 association with smoking status, secondary smoking exposure during pregnancy, and health
58 outcomes in offspring measured after birth. The epigenetic maternal smoking score was strongly
59 associated with smoking status during pregnancy ($p = 1.04 \times 10^{-23}$) and self-reported smoking
60 exposure ($p = 6.56 \times 10^{-8}$) in White Europeans, but not with self-reported exposure ($p > 0.05$) in
61 South Asians. The same score was consistently associated with smaller birth size ($p = 1.19 \times 10^{-6}$)
62 and lower birth weight ($p = 8.79 \times 10^{-7}$) in the combined South Asian and White European cohorts.
63 This cord blood epigenetic score can help identify babies exposed to maternal smoking and
64 assess its long-term impact on growth. Notably, even minimal smoking exposure in South Asian
65 mothers who were not active smokers showed a DNAm signature of small body size and low
66 birthweight in newborns.

67

68

69 **Introduction**

70 Maternal smoking has adverse effects on offspring health including pre-term delivery (1,2),
71 stillbirth (3), and low birth weight (4), and is associated with pregnancy complications such as
72 maternal higher blood pressure, and gestational diabetes (5). Consistent with the Developmental
73 Origins of Health and Disease (DOHaD) hypothesis, maternal smoking exposes the developing
74 fetus to harmful chemicals in tobacco that negatively impact the health of newborns, resulting in
75 early-onset metabolic diseases, such as childhood obesity (6–9). Yet self-reported smoking status
76 is subject to underreporting among pregnant women (10–12). This could subsequently impact the
77 effectiveness of interventions aimed at reducing smoking during pregnancy and may skew data
78 on the risks associated with maternal smoking.

79
80 Differential DNA methylation has been established as a reliable biochemical response to
81 cigarette smoking and was shown to capture the long-lasting effects of persistent smoking in ex-
82 smokers (13–15). Recent large epigenome-wide association studies (EWAS) have robustly
83 identified differentially methylated cytosine–phosphate–guanine (CpG) sites associated with
84 adult smoking (14,16,17) and maternal smoking (18,19). Our recent systematic review of 17 cord
85 blood epigenome-wide association studies (EWAS) demonstrated that out of the 290 CpG sites
86 reported, 19 sites were identified in more than one study; all of them associated with maternal
87 smoking (20). Furthermore, these findings have led to a more thorough investigation of the
88 epigenetic mechanisms underlying associations between well-established epidemiological
89 exposures and outcomes, such as the relationship between maternal smoking and birth weight in
90 Europeans (19,21–24) and the less studied African American populations (23) as well as between
91 maternal diet and cardiovascular health (25).

92

93 The majority of cohort studies have focused on participants of European ancestry, but
94 few were designed to assess the influence of maternal exposures on DNA methylation changes in
95 non-Europeans (23,26). It has been suggested that ancestral background could influence both
96 systematic patterns of methylation (27), such as cell composition and smoking behaviours (28).
97 These systematic differences also contribute to different smoking-related methylation signals at
98 individual CpGs (29). Thus, a comparative study of maternal smoking exposure is a first step
99 towards generalizing existing EWAS results to other populations and a necessary step towards
100 addressing health disparities that exist between populations due to societal privilege, including
101 race or ethnicity and socioeconomic factors.

102

103 A promising direction in epigenetic studies of adult smoking is the application of a
104 methylation score (30); this strategy can also be applied to disseminate current knowledge on
105 differential DNA methylation studies of maternal smoking. A methylation score is usually tissue-
106 specific and combines information from multiple CpGs using statistical models (31). Reducing
107 the number of predictors and measurement noise in the data can lead to better statistical power
108 and more interpretable effect sizes. It is also of interest to determine whether methylation scores
109 demonstrate the capacity to predict outcomes in diverse human populations, given the presence
110 of systematic differences in methylation patterns due to ancestral backgrounds (27).

111

112 In this paper, we investigated the epigenetic signature of maternal smoking on cord blood
113 DNA methylation in newborns, as well as its health consequences for newborn and later life
114 outcomes in one South Asian which refers to people who originate from the Indian subcontinent,

115 and two predominantly European-origin birth cohorts. Similar to the Born in Bradford study (32),
116 we observed several differentiating epidemiological characteristics between South Asian and
117 European-origin mothers. Notably, almost none of the South Asian mothers were current
118 smokers and had low smoking rates pre-pregnancy as compared to European mothers, which is
119 consistent with the broader trends of lower smoking rates in South Asian females (33). Another
120 relevant observation is the small birth size and low birth weight in the South Asian newborns.
121 These differences in newborn size and weight may be influenced by various factors, including
122 maternal nutrition, genetics, and socioeconomic status. Keeping these differences in mind, we
123 first conducted cohort-specific epigenetic association studies between available CpGs and
124 maternal smoking in the predominantly European-origin cohorts, benchmarking with previously
125 identified CpGs for maternal smoking and adult smoking. Second, we leveraged the reported
126 summary statistics from existing large EWASs to construct a methylation risk score (MRS) for
127 maternal smoking. The MRS was first internally validated in one of the European-origin cohorts
128 and then tested in a second independent European-origin cohort. Third, we examined the
129 association between maternal smoking MRS and newborn health outcomes, including length,
130 weight, body mass index (BMI), ponderal index, and early-life anthropometrics in both European
131 and South Asian cohorts.

132

133

134 **Results**

135

136 **Cohort Sample Characteristics**

137 The analyses included 763 European mother-child pairs with cord blood DNAm data from the
138 Canadian Healthy Infant Longitudinal Development (CHILD; $n = 352$) study and The Family
139 Atherosclerosis Monitoring In earLY life (FAMILY; $n = 411$) study (34), and 880 South Asian
140 mother-child pairs from The SouTh Asian biRth cohort (START) study (35). We observed
141 lower past smoking and missingness on smoking history among pregnant women in START as
142 compared to CHILD or FAMILY using the epigenetic subsample (Table 1) and the overall
143 sample (Supplementary Table 2). Pregnant women in START were significantly different from
144 CHILD or FAMILY in that they were on average younger at delivery, had a lower BMI, and a
145 higher rate of GDM, in line with other cohort studies in South Asian populations (36,37). As
146 compared to START, newborn infants from CHILD and FAMILY had a longer gestational
147 period, a higher birth weight, and a higher BMI at birth (Table 1; Supplementary Table 2). We
148 observed no difference between cohorts in terms of parity or newborn sex in the epigenetic
149 subsample (Table 1).

150
151 Within the European epigenetic subsample, of the 744 mother–newborn pairs with
152 complete smoking history data, 40 (5.3%) newborns were exposed to current maternal smoking,
153 which is on the lower end of the spectrum for the prevalence of smoking during pregnancy
154 (9.2%-32.5%) among Canadians (38). In addition, mothers who smoked during pregnancy were
155 on average younger, had fewer years of education, and had higher household exposure to
156 smoking (Supplementary Table 4). However, there was no statistically significant difference
157 between newborns exposed to current and none or previous smoking in terms of birth weight,
158 birth length, gestational age, or cell compositions.

159

160

161 **Epigenetic Association of Maternal Smoking in White Europeans**

162

163 The two predominantly White European cohorts, FAMILY ($n = 397$) and CHILD ($n = 347$),
164 contributed to the meta-analysis of maternal smoking for both the primary outcome of current
165 smoking (Figure 1-A) and the secondary outcome of ever smoking (Supplementary Figure 1).

166 The most significant associated CpGs with current maternal smoking were mapped to the growth
167 factor independent 1 (*GFII*) gene on chromosome 1, with cg12876356 as the lead (meta-
168 analyzed $p = 2.6 \times 10^{-6}$; $q = 0.006$; Table 2). There were no CpGs associated with the ever-smoker
169 status at an FDR of 0.05, though the top signal also coincided with the *GFII* gene
170 (Supplementary Figure 1). The meta-analysis of smoking exposure (hours per week) associations
171 in the European-origin cohorts (Figure 1-B) identified only one CpG on chromosome 17,
172 ccg01798813, that was also associated with maternal smoking and was consistent in the direction
173 of association (Table 2). However, the meta-analysis of the combined samples including the
174 South Asians from the START cohort did not yield any significant associations (Supplementary
175 Figure 2).

176

177 The EWAS in CHILD did not yield significant CpGs after FDR correction
178 (Supplementary Figure 3 and Supplementary Figure 4-A). The South Asian EWAS ($n=504$)
179 identified 474 CpGs at $FDR < 0.05$, although some of these corresponded to previously
180 identified CpGs for maternal smoking in Europeans (Supplementary Figure 4-B; highlighted in
181 red).

182

183

184 **Methylation Risk Score (MRS) Captures Maternal Smoking and Smoking Exposure**

185

186 The final MRSs, validated using CHILD European samples, included 11 and 114 CpG markers
187 (Supplementary Tables 5-6) from the targeted array and the epigenome-wide HM450 array,
188 respectively. Both produced methylation scores that were significantly associated with maternal
189 smoking history (Supplementary Figure 5). There was no statistically significant difference
190 between the two scores in all samples ($p = 1.00$) or among non-smokers ($p = 0.24$). Thus, we
191 proceeded with the simpler MRS model constructed using the 11 CpGs in subsequent analyses
192 for compatibility across cohorts.

193

194 The MRS was significantly associated with maternal smoking history in CHILD and
195 FAMILY (Figure 2), but not in START – not surprisingly – due to the low number of ever-
196 smokers ($n = 5$). A weak dose-dependent relationship between the MRS and the four categories
197 of maternal smoking status in the severity of exposure ([0] = never smoked; [1] = quit before this
198 pregnancy; [2] = quit during this pregnancy; [3] = currently smoking) was present in CHILD but
199 was not replicated in FAMILY. The areas under the Receiver Operating Characteristic (ROC)
200 curve (area under the curve or AUC) for detecting current smokers were 0.86 and 0.90 in CHILD
201 and FAMILY, respectively, while the AUCs for detecting ever-smokers were 0.61 and 0.60,
202 respectively. Meanwhile, the maternal smoking MRS was significantly associated with increased
203 smoking exposure in the two White European cohorts ($p = 6.91 \times 10^{-4}$ in CHILD and $p =$
204 1.35×10^{-5} in FAMILY; Supplementary Table 7), but not in the South Asian birth cohort.

205

206 Among individuals who had never smoked, no statistically significant mean difference
207 was observed in the distribution of the combined methylation score nor individual CpGs that
208 contributed to the score between South Asian and European cohorts (Supplementary Figure 6).
209 One CpG had a significant difference in variance (Supplementary Table 8), though it did not
210 change the conclusion that there was no difference in mean, variance, and overall distribution of
211 the combined methylation score. These results provided empirical support for the portability of a
212 European-derived maternal smoking methylation score to South Asian populations.

213

214 **Association between MRS and Offspring Anthropometrics**

215

216 A higher maternal smoking MRS was significantly associated with lower birth weight and
217 smaller birth size in both the European and South Asian cohorts (Table 3; Supplementary Table
218 7). The meta-analysis revealed no heterogeneity in the direction nor the effect size of
219 associations between populations. The association between the MRS and several health metrics,
220 including height or length, weight, and skinfolds, appeared to persist with similar estimated
221 effects throughout early developmental years (Supplementary Tables 7 and 9), albeit the most
222 significant effects were at birth, and the significance attenuated at later visits.

223

224

225 **Discussion**

226

227 We examined the epigenetic signature of maternal smoking and smoking exposure using
228 newborn cord blood samples from predominately European-origin and South Asian cohorts via

229 two strategies: an individual CpG-level EWAS approach, and a multivariate approach in the
230 form of a methylation score. The EWAS results replicated the association between maternal
231 smoking and CpGs in the *GFII* gene that is well described in the literature with respect to
232 smoking (14,16), maternal smoking (18,19,39,40), and birth weight (22). In the latter case, we
233 observed a significant association with maternal smoking history and smoking exposure in
234 European-origin newborns. Further, we noted a weak dose-dependent relationship between
235 maternal smoking history and the methylation score in one European cohort (CHILD) but this
236 was not replicated in the other (FAMILY). Since the timing and duration of maternal smoking
237 during pregnancy were not directly available, these differences could play a role in the
238 magnitude and specificity of DNA methylation changes in cord blood. Finally, the significant
239 association of the MRS with the newborn health metrics in START, in the absence of mothers'
240 active smoking, could be the result of underreporting of smoking, poor recall of the time of
241 quitting, and/or due to air pollution exposure (41), leading to oxidative stress. This suggests that
242 our cord blood DNAm signature of maternal smoking is perhaps not unique to cigarette smoking,
243 but captures similar biochemical responses, for example, via the aryl hydrocarbon receptor
244 (42,43). Our observation that a higher MRS was associated with lower birth weight and smaller
245 birth length in both ethnic populations is thus consistent with the established link between
246 oxidative stress and metabolic syndrome (44).

247
248 Contrary to DNA methylation studies of smoking in adults, where whole blood is often
249 used as a proxy tissue, there are multiple relevant tissues for maternal smoking during pregnancy,
250 including the placenta of the mother, newborn cord blood, and children's whole blood. However,
251 methylation changes measured in whole blood or placenta of the mother, or cord blood of infants

252 showed substantially different patterns of association signals (45). Since methylation signals are
253 known to be tissue-specific, it would be of interest for future research to combine differential
254 methylation patterns from all relevant tissue to assess the immediate and long-term effects of
255 maternal smoking. Another direction to further this line of research is to explore postnatal factors
256 that mitigate prenatal exposures, for example, breastfeeding, which has been shown to have a
257 protective effect against maternal tobacco smoking (46). Indeed, more research is necessary to
258 understand the critical periods of exposure and the dose-response relationship between maternal
259 smoking and cord blood DNA methylation changes. Ongoing efforts to monitor the offspring and
260 collect data in the next decade are in progress to establish the long-term association between
261 maternal smoking and cardio-metabolic health (34,35). As such, the constructed MRS can
262 facilitate future research in child health and will be included as part of the generated data for
263 others to access.

264

265 The strengths of this report include ethnic diversity, and fine phenotyping in a
266 prospective and harmonized way with follow-up at multiple early childhood stages. This work is
267 the first major multi-ancestry study that utilizes methylation scores to study maternal smoking
268 and examines their portability from European-origin populations to South Asians. The use of
269 MRS, as compared to individual CpGs, is a powerful tool to systematically investigate the
270 influence of DNA methylation changes and whether it has lasting functional consequences on
271 health outcomes. Our results converge with previous findings that epigenetic associations of
272 maternal smoking are associated with newborn health, and add to the small body of evidence that
273 these relationships extend to non-European populations and that different ancestral populations
274 can experience the early developmental periods differently.

275

276 A few limitations should be mentioned. In the context of existing epigenetic studies of
277 maternal smoking, we were not able to replicate signals in other well-reported genes such as
278 *AHRR*, *CYP1A1*, and *MYO1G*, however, the MRS was able to pick up signals from these genes
279 (Supplementary Table 5). This could be due to several reasons. First, the customized array was
280 designed in 2016 and many large EWASs on smoking and maternal smoking conducted more
281 recently had not been included. However, we have shown that from a multivariate perspective,
282 the MRS constructed using a targeted approach that was carefully designed can be equally
283 powerful with the advantage of being cost-effective. Second, contrary to existing EWASs where
284 the methylation values are typically treated as the outcome, and the exposure, such as smoking,
285 as the predictor; we reversed the regression such that the methylation levels were the predictors
286 and smoking exposure as the outcome. This reverse regression approach is robust and our choice
287 to reverse the regression was motivated by the goal of constructing a smoking score that
288 combines the additive effects at multiple CpGs, which would otherwise be unfeasible. Fourth,
289 systematic ancestral differences in DNA methylation patterns had been shown to vary at
290 individual CpGs in terms of their association with smoking (29). Converging with this
291 conclusion, we also found the association with *GFII* to be most consistent after adjusting for cell
292 composition. Finally, maternal smoking is often associated with other confounding factors, such
293 as socioeconomic status, other lifestyle behaviours, and environmental exposures. While we have
294 done our best to control for well-known confounders that were available by study design, as in
295 all observational studies, we could not account for unknown confounding effects.

296

297 In conclusion, the epigenetic maternal smoking score we constructed was strongly
298 associated with smoking status during pregnancy and self-reported smoking exposure in White
299 Europeans, and with smaller birth size and lower birth weight in the combined South Asian and
300 White European cohorts. The proposed cord blood epigenetic signature of maternal smoking has
301 the potential to identify newborns who were exposed to maternal smoking *in utero* and to assess
302 the long-term impact of smoking exposure on offspring health. In South Asian mothers with
303 minimal smoking behaviour, the relationship between the methylation score and negative health
304 outcomes in newborns is still apparent, indicating that DNA methylation response is sensitive to
305 smoking exposure, even in the absence of active smoking.

306

307

308 **Material and Methods**

309

310 **Study population**

311

312 The NutriGen Alliance is a consortium consisting of four prospective, population-based birth
313 cohorts that enrolled birthing mother and newborn pairs in Canada. Details of these cohorts have
314 been described elsewhere (47). The current investigation focused on i). European-origin
315 offspring from the population-based CHILD study who were selected for methylation analysis,
316 ii). The Family Atherosclerosis Monitoring In early life (FAMILY) study that is predominately
317 European-origin, and iii). The SouTh Asian biRth cohorr (START) study that is exclusively
318 comprised of people who originated from the Indian subcontinent known as South Asians. The
319 ethnicity of the parents was self-reported and recorded at baseline in all three cohorts. Biological

320 samples, clinical assessments, and questionnaires were used to derive health phenotypes and an
321 array of genetic, epigenetic, and metabolomic data. The superordinate goal of the NutriGen study
322 is to understand how nutrition, environmental exposures, and physical health of mothers impact
323 the health and early development of their offspring using a multi-omics approach.

324

325 **Methylation data processing and quality controls**

326

327 Newborn cord blood samples were processed using two methylation array technologies. About
328 half of the START samples and selected samples from CHILD were hybridized to the Illumina
329 Human-Methylation450K BeadChip (HM450K) array, which covers CpGs in the entire genome
330 (48). The raw methylation data were generated by the Illumina iScan software and separately pre-
331 processed for START and CHILD using the “*sesame*” R package following pipelines designed
332 for HM450K BeadChip (49). The remaining START and all FAMILY samples were profiled
333 using a targeted array based on the Infinium Methylation EPIC designed by the Genetic and
334 Molecular Epidemiology Laboratory (GMEL; Hamilton, Canada). The GMEL customized array
335 includes ~3000 CpG sites that were previously reported to associate with complex traits or
336 exposures and was designed to maximize discovery while keeping the costs of profiling
337 epigenome-wide DNA methylation down. The targeted methylation data were pre-processed
338 using a customized quality control pipeline and functions from the “*sesame*” R package
339 recommended for EPIC.

340

341 Pre-processed data were then used to derive the β -value matrix, where each column gives
342 the methylation level at a CpG site as a ratio of the probe intensity to the overall probe intensity.

343 Additional quality control filters were applied to the final beta-value matrices to remove samples
344 with > 10% missing probes and CpG probes with >10% samples missing. Cross-reactive probes
345 and SNP probes were removed as recommended for HM450 (50) and EPIC arrays (51,52). For
346 CpG probes with a missing rate <10%, mean imputation was used to fill in the missing values.
347 We further excluded samples that were either mismatches between reported sex and methylation-
348 inferred sex or were duplicates. Finally, considering the low prevalence of smokers, we sought to
349 reduce spurious associations by removing non-informative probes that were either all
350 hypomethylated (β -value < 0.1) or hypermethylated (β -value > 0.9), which have been shown to
351 have less optimal performance (53). A summary of the sample and probe inclusion/exclusion is
352 shown in Supplementary Table 1. A detailed description of pre-processing and quality control
353 steps is included in Supplementary Material.

354
355 Cell-type proportions (CD8T, CD4T, Natural Killer cells, B cells, monocytes,
356 granulocytes, and nucleated red blood cells) were estimated following a reference-based
357 approach developed for cord blood (54) and using R packages
358 “*FlowSorted.CordBloodCombined.450k*” and “*FlowSorted.Blood.EPIC*”. All data processing
359 and subsequent analyses were conducted in R v.4.1.0 (55).

360
361 **Phenotype data processing and quality controls**

362
363 At the time of enrollment, all pregnant women completed a comprehensive questionnaire that
364 collected information on prenatal diet, smoking, education, socioeconomic factors, physical
365 activities and health as detailed previously (34,35). Maternal smoking history (0=never smoked,

366 1=quit before this pregnancy, 2=quit during this pregnancy, or 3=current smoker) was assessed
367 during the second trimester (at baseline). Smoke exposure was measured as “number of hours
368 exposed per week”. Gestational diabetes mellitus (GDM) was determined based on a
369 combination of oral glucose tolerance test (OGTT), self-report, and reported diabetic treatments
370 (insulin, pills, or restricted diet). For South Asian mothers in START, the same OGTT threshold
371 as Born in Bradford (26,32) was used, while the International Association of the Diabetes and
372 Pregnancy Study Groups (IASDPSG) criteria (56) for OGTT were used in CHILD and FAMILY
373 cohorts.

374
375 All newborn anthropometric measurements, including length, weight, waist, waist-hip-
376 ratio (WHR), BMI, were collected at the time of birth. The newborns were then followed up at 1,
377 2, 3, and 5 years of age and provided basic anthropometric measurements, including height,
378 weight, BMI, sum of the skinfolds (triceps skinfold and subscapular skinfold), WHR, as well as
379 additional environmental exposures.

380
381 **Phenotype and Methylation Data Consolidation**

382
383 The current investigation examines the impact of maternal smoking or smoke exposure on DNA
384 methylation derived from newborn cord blood in START and the two predominately European
385 cohorts (CHILD and FAMILY). To maximize sample size in FAMILY and CHILD, we retained
386 either self-identified or genetically confirmed Europeans (Supplementary Table 2). The cohorts
387 consist of representative population samples without enrichment for any clinical conditions,
388 though only singleton mothers were invited to participate.

389

390 The final analytical datasets, after combining the quality-controlled methylation data and
391 phenotypic data, included 352, 411, and 890 mother-newborn pairs from CHILD, FAMILY, and
392 START, respectively. Demographic characteristics and relevant covariates of the epigenetic
393 subsample and the overall sample are summarized in Table 1 and Supplementary Table 3,
394 respectively.

395

396 **Epigenome-Wide Association of Maternal Smoking in European Cohorts**

397

398 Since there were no current smokers in START (Table 1), we tested the association between
399 maternal smoking and differential methylated sites in FAMILY (# of CpG = 2,544) and CHILD
400 (# of CpG = 358,113). The primary outcome variable was “current smoker”, defined by mothers
401 self-identified as currently smoking during the pregnancy vs. those who never smoked or quit
402 either before or during pregnancy. As a sensitive analysis, we included a secondary outcome
403 variable “ever smoker”, defined by mothers who are current smokers or have quit smoking vs.
404 those who never smoked. A tertiary outcome was smoking exposure, measured by the number of
405 hours a week reported by the expectant mothers, and was available in all cohorts. We
406 summarized the type of analyses for different outcomes in Supplementary Table 3.

407

408 We first conducted a separate epigenetic association study in each cohort, testing the
409 association between methylation β -values at individual CpGs and the smoking phenotype using
410 either a logistic regression model for smoking status or a linear regression for smoking exposure
411 as the outcome. The model adjusted for additional covariates including the estimated cell

412 compositions, maternal age, social disadvantage index, which is a continuous composite measure
413 of social and economic exposures (57), mother's years of education, GDM, and parity. The
414 smoking exposure variable was skewed, and a rank-based transformation was applied to mimic a
415 standard normal distribution.

416
417 We then meta-analyzed association results for maternal smoking status in the European
418 cohorts using an inverse variance-weighted fixed-effect model. The meta-analysis was conducted
419 for 2,112 CpGs that were available in both CHILD (HM450K) and FAMILY (GMEL-EPIC).
420 For the tertiary outcome, we conducted a meta-analysis including START using both a fixed-
421 effect and a random-effect model to account for the potential heterogeneity. For each EWAS or
422 meta-analysis, false discovery rate (FDR) adjustment was used to control multiple testing and we
423 considered an FDR-adjusted p -value < 0.05 to be statistically significant.

424
425 **Using DNA Methylation to Construct Predictive Models for Maternal Smoking**

426
427 We sought to construct a predictive model in the form of a methylation risk score (MRS) using
428 reported associations of maternal smoking. The proposed solution adapted the existing lassosum
429 method (58) that was originally designed for polygenic risk scores, where the matrix of SNP
430 genotypes (X) can be conveniently replaced by the β -value matrix. For more details, see the
431 Supplementary Material. Briefly, an objective function under elastic-net constraint was
432 minimized to obtain the elastic-net solution γ , where only summary statistics (b) and a scalar of
433 the covariance between the β -values of the CpGs ($X'X$) are needed. The tuning parameters λ_1
434 and λ_2 were chosen by validating on the observed smoking history (as a continuous outcome) in

435 CHILD that produced the most significant model. The optimized λ_1 and λ_2 were then used to
436 create a final model that entails a list of CpGs and their corresponding weights, which were then
437 used to calculate a MRS for maternal smoking in the FAMILY and START samples.

438
439 The summary statistics of the discovery EWAS were obtained from EWAS catalog
440 (<http://www.ewascatalog.org/>) reported under “PubMed ID 27040690” by Joubert and
441 colleagues (18). The summary statistics were first screened to retain CpGs with sample size
442 above 5000, and then restricted to analysis that examined “sustained maternal smoking in
443 pregnancy effect on newborns adjusted for cell composition”. Of the 2620 maternal smoking
444 CpGs that passed the initial screening, 1,902 were available in CHILD but only 125 were
445 common to CHILD, FAMILY, and START. To evaluate whether the targeted GMEL-EPIC
446 array design has comparable performance as the epigenome-wide array to evaluate the epigenetic
447 signature of maternal smoking, two MRSs were constructed, one using the 125 CpGs available in
448 all cohorts – across the HM450K and targeted GMEL-EPIC arrays – and another using 1,902
449 CpGs that were only available in CHILD and a subset of START samples.

450
451 For the MRS constructed using the 125 common CpGs, we empirically assessed whether
452 the resulting score was portable to the START cohort by examining the distribution of the final
453 score as well as individual CpGs that contributed to the score among never smokers in terms of
454 mean difference using an analysis of variance F -test, the variance difference using a Levene’s
455 test, and the overall distribution using a non-parametric Anderson-Darling test.

456

457 Finally, we tested the association between each maternal smoking MRS and smoking
 458 phenotypes in mothers, as well as offspring phenotypes, when applicable, adjusting for the
 459 child’s age at each visit. The association results were meta-analyzed for phenotypes with
 460 homogeneous effects across the cohorts using a fixed-effect model.

461
 462 **Table 1. Characteristics of the epigenetic subsample (1,650 mother–newborn pairs) from**
 463 **the CHILD, FAMILY, START cohorts.**

| | CHILD- HM450K* (N=352) | FAMILY- GMEL** (N=411) | START- HM450* (N=504) | START- GMEL** (N=376) | P- value |
|-----------------------------------|--------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|---------------------|
| Smoking History | | | | | |
| never smoked | 247 (70.2%) | 253 (61.6%) | 501 (99.4%) | 371 (98.7%) | <0.001 |
| quit before this pregnancy | 72 (20.5%) | 58 (14.1%) | 1 (0.2%) | 2 (0.5%) | |
| quit during this pregnancy | 17 (4.8%) | 57 (13.9%) | 1 (0.2%) | 1 (0.3%) | |
| currently smoking | 11 (3.1%) | 29 (7.1%) | 0 (0%) | 0 (0%) | |
| Missing | 5 (1.4%) | 14 (3.4%) | 1 (0.2%) | 2 (0.5%) | |
| Smoking Exposure (hr/week) | | | | | |
| Mean (SD) | 0.97 (± 7.6) | 0.36 (± 1.8) | 0.33 (± 2.7) | 0.33 (± 3.1) | <0.001 |
| Missing | 12 (3.4%) | 5 (1.2%) | 42 (8.3%) | 7 (1.9%) | |
| GDM | | | | | |
| YES | 16 (4.5%) | 345 (83.9%) | 183 (36.3%) | 142 (37.8%) | <0.001 |
| NO | 336 (95.5%) | 66 (16.1%) | 320 (63.5%) | 231 (61.4%) | |
| Missing | 0 (0%) | 0 (0%) | 1 (0.2%) | 3 (0.8%) | |
| Years of Education | | | | | |
| Mean (SD) | 16 (± 2.9) | 17 (± 3.4) | 16 (± 2.4) | 16 (± 2.2) | <0.001 |
| Missing | 7 (2.0%) | 3 (0.7%) | 0 (0%) | 0 (0%) | |
| Mother's Age | | | | | |
| Mean (SD) | 33 (± 4.5) | 32 (± 5.3) | 30 (± 3.9) | 30 (± 3.8) | <0.001 |
| Missing | 4 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Parity | | | | | |
| Mean (SD) | 0.72 (± 0.88) | 0.80 (± 1.0) | 0.80 (± 0.81) | 0.74 (± 0.83) | 0.186 |
| Missing | 2 (0.6%) | 0 (0%) | 13 (2.6%) | 7 (1.9%) | |
| Pre-pregnancy BMI | | | | | |

| | | | | | |
|---------------------------------------|------------------|-----------------|-----------------|-----------------|--------|
| Mean (SD) | 25 (± 5.4) | 26 (± 6.4) | 24 (± 4.4) | 24 (± 4.6) | <0.001 |
| Missing | 132 (37.5%) | 16 (3.9%) | 2 (0.4%) | 2 (0.5%) | |
| Newborn Sex | | | | | |
| Male | 194 (55.1%) | 211 (51.3%) | 239 (47.4%) | 188 (50.0%) | 0.168 |
| Female | 158 (44.9%) | 200 (48.7%) | 265 (52.6%) | 188 (50.0%) | |
| Plant Based Diet | | | | | |
| Mean (SD) | -0.48 (± 0.46) | 0.19 (± 0.67) | 1.6 (± 1.1) | 1.4 (± 1.1) | <0.001 |
| Missing | 23 (6.5%) | 36 (8.8%) | 16 (3.2%) | 13 (3.5%) | |
| Health Conscious Diet | | | | | |
| Mean (SD) | 0.21 (± 0.81) | -0.73 (± 0.73) | -0.42 (± 0.79) | -0.47 (± 0.70) | <0.001 |
| Missing | 23 (6.5%) | 36 (8.8%) | 16 (3.2%) | 13 (3.5%) | |
| Western Diet | | | | | |
| Mean (SD) | -0.15 (± 0.63) | 1.1 (± 1.2) | -0.51 (± 0.65) | -0.51 (± 0.64) | <0.001 |
| Missing | 23 (6.5%) | 36 (8.8%) | 16 (3.2%) | 13 (3.5%) | |
| Gestational Age (weeks) | | | | | |
| Mean (SD) | 40 (± 1.4) | 39 (± 1.5) | 39 (± 1.3) | 39 (± 1.3) | <0.001 |
| Missing | 4 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Birth Length (cm) | | | | | |
| Mean (SD) | 52 (± 2.5) | 50 (± 2.2) | 51 (± 2.7) | 51 (± 2.4) | <0.001 |
| Missing | 71 (20.2%) | 10 (2.4%) | 7 (1.4%) | 8 (2.1%) | |
| Birth Weight (kg) | | | | | |
| Mean (SD) | 3.5 (± 0.49) | 3.5 (± 0.50) | 3.3 (± 0.46) | 3.2 (± 0.45) | <0.001 |
| Missing | 6 (1.7%) | 0 (0%) | 1 (0.2%) | 1 (0.3%) | |
| Newborn BMI (kg/m²) | | | | | |
| Mean (SD) | 13 (± 1.4) | 14 (± 1.3) | 12 (± 1.4) | 12 (± 1.4) | <0.001 |
| Missing | 72 (20.5%) | 10 (2.4%) | 7 (1.4%) | 8 (2.1%) | |
| Newborn Ponderal Index | | | | | |
| Mean (SD) | 25 (± 3.1) | 28 (± 2.5) | 24 (± 3.2) | 25 (± 3.2) | <0.001 |
| Missing | 2 (0.6%) | 10 (2.4%) | 7 (1.4%) | 8 (2.1%) | |
| CD8T | | | | | |
| Mean (SD) | 0.0094 (± 0.014) | 0.040 (± 0.031) | 0.019 (± 0.024) | 0.056 (± 0.028) | <0.001 |
| CD4T | | | | | |
| Mean (SD) | 0.11 (± 0.056) | 0.13 (± 0.060) | 0.16 (± 0.069) | 0.15 (± 0.054) | <0.001 |
| NK | | | | | |
| Mean (SD) | 0.021 (± 0.024) | 0.031 (± 0.028) | 0.019 (± 0.026) | 0.028 (± 0.031) | <0.001 |
| Bcell | | | | | |
| Mean (SD) | 0.024 (± 0.021) | 0.042 (± 0.030) | 0.043 (± 0.033) | 0.055 (± 0.028) | <0.001 |

| | | | | | |
|------------------|----------------------|----------------------|----------------------|----------------------|--------|
| Mono | | | | | |
| Mean (SD) | 0.013 (\pm 0.019) | 0.045 (\pm 0.029) | 0.027 (\pm 0.031) | 0.074 (\pm 0.035) | <0.001 |
| Gran | | | | | |
| Mean (SD) | 0.80 (\pm 0.096) | 0.60 (\pm 0.13) | 0.72 (\pm 0.14) | 0.49 (\pm 0.13) | <0.001 |
| nRBC | | | | | |
| Mean (SD) | 0.078 (\pm 0.084) | 0.12 (\pm 0.11) | 0.069 (\pm 0.11) | 0.14 (\pm 0.11) | <0.001 |
| MNLR | | | | | |
| Mean (SD) | 6.6 (\pm 6.0) | 3.3 (\pm 3.1) | 4.0 (\pm 3.1) | 1.9 (\pm 0.98) | <0.001 |
| Missing | 6 (1.7%) | 0 (0%) | 3 (0.6%) | 0 (0%) | |

464 * HM450 array

465 ** EPIC customized array from GMEL

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483 **Table 2. Meta-analysis results of maternal smoking and smoking exposure that were**
 484 **significant after false discovery rate correction in European cohorts.**

| | CHR | Probe_ID | Position | Estimate | Std..Error | Pvalue | HetPval | CHILD | FAMILY | UCSC Ref Gene | FDR | Reported Association EWAS catalog |
|-------------------------|-----|----------------------------|------------|----------|------------|----------|---------|---------|----------|---------------|--------|-----------------------------------|
| Maternal Smoking | | | | | | | | | | | | |
| | 1 | cg12876356 | 92481269 | -1.11 | 0.22 | 7.33E-07 | 0.51 | 0.02 | 9.45E-06 | <i>GF11</i> | 0.0019 | MS;S; AC; BW |
| | 1 | cg09935388 | 92482032 | -1.15 | 0.24 | 2.26E-06 | 0.52 | 0.02 | 2.71E-05 | <i>GF11</i> | 0.0029 | MS;GA; S; AC; BMI; BW |
| | 1 | cg14179389 | 92482405 | -1.48 | 0.32 | 5.03E-06 | 0.73 | 0.01 | 1.12E-04 | <i>GF11</i> | 0.0035 | MS;S |
| | 1 | cg18146737 | 92481144 | -0.92 | 0.20 | 5.58E-06 | 0.50 | 0.04 | 3.95E-05 | <i>GF11</i> | 0.0035 | MS;S; AC; BW |
| | 1 | cg09662411 | 92480576 | -0.94 | 0.22 | 1.64E-05 | 0.29 | 0.10 | 3.85E-05 | <i>GF11</i> | 0.0083 | MS;S |
| | 1 | cg18316974 | 92481479 | -0.74 | 0.18 | 3.58E-05 | 0.33 | 0.13 | 7.34E-05 | <i>GF11</i> | 0.0152 | MS;S; AC; BW |
| | 17 | cg01798813 | 2494783943 | -0.83 | 0.21 | 1.09E-04 | 0.34 | 0.02 | 1.59E-03 | NA | 0.0395 | A; GA; BMI |
| Smoking Exposure | | | | | | | | | | | | |
| | 1 | cg09935388 | 92482032 | -0.18 | 0.04 | 1.39E-05 | 0.23 | 0.15 | 2.45E-05 | <i>GF11</i> | 0.04 | MS;GA; S; AC MI; BW |
| | 17 | cg01798813 | 2494783943 | -0.18 | 0.04 | 3.30E-05 | 0.13 | 0.00035 | 0.013 | NA | 0.04 | A; GA; BMI |

485

486

487 MS: maternal smoking

488 GA: gestational age

489 AC: alcohol consumption

490 BMI: body mass index

491 T2D: type 2 diabetes

492 A: age

493 BW: birth weight

494

495

496

497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513

Table 3. Significant associations between maternal smoking methylation risk score and phenotypes in CHILD, FAMILY and START.

| | Meta-analyzed Effect | Std. Error | Pvalue | HetPval | q-value | START HM450* | START GMEL** | CHILD HM450* | FAMILY GMEL** |
|-----------------------------------|----------------------|------------|----------|---------|----------|--------------|--------------|--------------|---------------|
| Smoking Exposure (hr/week) | 0.12 | 0.02 | 5.68E-07 | 0.03 | 3.69E-06 | 0.37 | 1.93E-01 | 6.91E-04 | 1.35E-05 |
| Birth Length (cm) | -0.31 | 0.06 | 4.46E-07 | 0.31 | 3.69E-06 | 4.25E-03 | 1.83E-04 | 0.050 | 0.105 |
| Birth Weight (kg) | -0.06 | 0.01 | 5.53E-07 | 0.80 | 3.69E-06 | 0.029 | 0.023 | 0.006 | 3.98E-03 |
| 1-year Length (cm) | -0.44 | 0.08 | 3.53E-08 | 0.45 | 9.18E-07 | 0.017 | 1.48E-04 | 0.021 | 7.76E-03 |
| 1-year Weight (kg) | -0.10 | 0.03 | 2.16E-03 | 0.92 | 9.38E-03 | 0.31 | 0.14 | 0.057 | 0.083 |
| 2-year Length (cm) | -0.48 | 0.11 | 2.02E-05 | 0.33 | 4.75E-05 | 0.010 | 0.00094 | 0.32 | 0.054 |
| 3-year Height (cm) | -0.27 | 0.11 | 0.014 | 0.92 | 0.047 | 0.43 | 0.32 | 0.20 | 0.074 |
| 3-year Skinfold | 0.45 | 0.12 | 2.25E-04 | 0.57 | 9.74E-04 | 0.37 | 0.41 | 0.012 | 0.0057 |

* HM450 array, ** EPIC customized array from GMEL

514

515

516 **Figure Legends:**

517

518 **Figure 1. Manhattan plots of the meta-analyzed association between cord blood DNAm and**
519 **maternal smoking in Europeans.**

520 Manhattan plots summarized the meta-analyzed association p -values between cord blood DNA
521 methylation levels and current maternal smoking (A) or smoking exposure (B) at a common set
522 of 2,114 CpG sites. The red line denotes the smallest $-\log_{10}(p\text{-value})$ that is below the FDR
523 correction threshold of 0.05. The red dots represent established associations with maternal
524 smoking reported in Joubert and colleagues (18).

525

526 **Figure 2. Relationships between maternal smoking MRS and maternal smoking history**
527 **categories for each of the studies.**

528

529 Maternal smoking methylation score (y-axis) was shown as a function of maternal smoking
530 history (x-axis) in levels of severity for prenatal exposure for each study. Each severity level was
531 compared to the never-smoking group and the corresponding two sample t -test p -value was
532 reported. An omnibus test p -value to test whether a mean difference in methylation score was
533 present among all smoking history categories.

534

535

536

537

538

539 **Supporting Information captions**

540

541 **Supplementary Methods.**

542

543 **Suppl. Table 1. Quality controls for the inclusion/exclusion of samples and methylation**
544 **probes.**

545

546 **Suppl. Table 2. Characteristics of the overall sample include 5176 mother–newborn pairs**
547 **from the CHILD, FAMILY, and START cohorts.**

548

549 **Suppl. Table 3. A summary of available analyses and outcome variables in each cohort.**

550

551 **Suppl. Table 4. Characteristics of the epigenetic subsample from CHILD and FAMILY**
552 **cohorts stratified by smoking status.**

553

554 **Suppl. Table 5. A summary of 11 CpGs available on the targeted array that contribute to**
555 **the final methylation risk score.**

556

557 **Suppl. Table 6. A summary of 114 CpGs available on the HM450 array that contribute to**
558 **the epigenome-wide methylation risk score.**

559

560 **Suppl. Table 7. Association between maternal smoking methylation risk score and**
561 **phenotypes in CHILD, FAMILY and START.**

562

563 **Suppl. Table 8. Association between maternal smoking methylation risk score and**
564 **phenotypes in CHILD and FAMILY.**

565

566 **Suppl. Table 9. A summary of statistical tests to evaluate the difference in distribution of**
567 **methylation score and relevant CpGs between South Asian and European cohorts.**

568

569 **Supplementary Figure 1. Manhattan plots of the meta-analyzed association between cord**
570 **blood DNA methylation and ever maternal smoking in Europeans.**

571 The meta-analyzed association p -values for ever maternal smoking and methylation levels at
572 2,114 CpG sites were summarized in the Manhattan plot. Ever maternal smoking was defined to
573 compare those who were currently smoking or quit before or during this pregnancy vs. those
574 never smoked. The red line denotes the smallest $-\log_{10}(p\text{-value})$ that is below the FDR
575 correction threshold of 0.05. The red dots represent established associations with maternal
576 smoking reported in Joubert and colleagues (18).

577

578 **Supplementary Figure 2. Manhattan plots of the meta-analyzed association between cord**
579 **blood DNA methylation and smoking exposure in the combined European and South Asian**
580 **cohorts.**

581 The meta-analyzed association p -values for smoking exposure and methylation levels at 2,114
582 CpG sites were summarized in the Manhattan plot. The red dots represent established
583 associations with maternal smoking reported in Joubert and colleagues (18).

584

585 **Supplementary Figure 3. Manhattan plots of the Epigenome-wide associations between**
586 **cord blood DNAm and maternal smoking in CHILD.**

587 Manhattan plots summarized the association p -values between cord blood DNA methylation
588 levels and current maternal smoking (A) or ever maternal smoking (B) at 200,050 CpG sites. The
589 red line denotes the smallest $-\log_{10}(p\text{-value})$ that is below the FDR correction threshold of 0.05.
590 The red dots represent established associations with maternal smoking reported in Joubert and
591 colleagues (18).

592

593 **Supplementary Figure 4. Manhattan plots of the Epigenome-wide associations between**
594 **cord blood DNAm and smoking exposure in CHILD and START.**

595 Manhattan plots summarized the association p -values between cord blood DNA methylation
596 levels and smoking exposure in CHILD (A) or START (B) at 200,050 and 218,982 CpG sites,
597 respectively. The red line denotes the smallest $-\log_{10}(p\text{-value})$ that is below the FDR correction
598 threshold of 0.05. The red dots represent established associations with maternal smoking
599 reported in Joubert and colleagues (18).

600

601 **Supplementary Figure 5. A comparison of results for maternal smoking MRS constructed**
602 **using the targeted array and an epigenome-wide arrays in CHILD.**

603 Maternal smoking methylation score (y-axis) was shown as a function of maternal smoking
604 history (x-axis) in levels of severity ([0] = never smoked; [1] = quit before this pregnancy; [2] =
605 quit during this pregnancy; [3] = currently smoking) for prenatal exposure for each study. Each
606 severity level was compared to the never smoking group and the corresponding two sample *t*-test
607 *p*-value was reported. An omnibus test *p*-value to test whether a mean difference in methylation
608 score was present among all smoking history categories.

609

610 **Supplementary Figure 6. Boxplots of methylation score and contributing CpGs stratified**
611 **by study.**

612 The boxplots captured the standardized maternal smoking methylation score and CpGs values (y-
613 axis) stratified by study. The top panels included CpGs that were positively correlated with
614 maternal smoking, or more methylated when exposed to prenatal smoking, while the bottom
615 panels included CpGs and the score that were negatively associated with maternal smoking.

616

617

618

619

620

621

622

623

624

625

626

627

628 **Acknowledgements**

629 We express our sincere gratitude to all the participating families and the START, FAMILY, and
630 CHILD study teams, including interviewers, nurses, computer and laboratory technicians,
631 clerical workers, research scientists, volunteers, managers, and receptionists.

632

633 We would like to acknowledge the Genetic and Molecular Epidemiology Laboratory (GMEL),
634 an associate of Hamilton Health Sciences and McMaster University, for their indispensable
635 contributions to this work. The technical staff of GMEL conducted all epigenetic profiling,
636 including sample processing and other technical operations.

637

638 We thank the members of the Nutrigen Alliance for providing the data: Sonia S. Anand;
639 Stephanie A. Atkinson; Meghan Azad; Allan B. Becker; Jeffrey Brook; Judah A Denburg;
640 Dipika Desai; Russell J. de Souza; Milan K. Gupta; Michael Kobor; Diana L. Lefebvre; Wendy
641 Lou; Piushkumar J. Mandhane; Sarah McDonald; Andrew Mente; David Meyre; Theo J. Moraes;
642 Katherine M. Morrison; Guillaume Paré; Malcolm R. Sears; Padmaja Subbarao; Koon K. Teo;
643 Stuart E. Turvey; Julie Wilson; Salim Yusuf; Gita Wahi; Michael A. Zulyniak.

644

645 This study was funded by the Canadian Institutes of Health Research Metabolomics Team Grant:
646 MWG-146332. Dr. Anand is supported by a Tier 1 Canada Research Chair in Ethnicity and CVD

647 and Heart, Stroke Foundation Chair in Population Health, a grant from the Canadian Partnership
648 Against Cancer, Heart and Stroke Foundation of Canada and Canadian Institutes of Health
649 Research. Dr. Azad is supported by a Tier 2 Canada Research Chair in the Developmental
650 Origins of Chronic Disease.

651 **Data availability statement**

652 The summary statistics used to construct methylation risk scores are available from EWAS
653 catalog at <http://www.ewascatalog.org/?trait=maternal%20smoking%20in%20pregnancy> with
654 additional filters of PubMID 27040690 and analysis on “Sustained maternal smoking in
655 pregnancy effect on newborns adjusted for cell composition”.

656
657 Summary statistics generated in the current study, including a total of 8 primary association
658 studies (three smoking phenotypes in three cohorts) and 3 sets of meta-analyzed results in
659 Europeans are available upon request. All scripts to reproduce and validate the predictive model
660 can be found at
661 <https://github.com/WeiAkaneDeng/EpigeneticResearch/tree/main/MaternalSmoking>.

663 **Conflicts of interest**

664 No conflict of interest.

665

666 **Ethics Statement**

667 Ethical approval was obtained independently from the Hamilton Integrated Research Ethics
668 Board: CHILD (REB 07–2929), FAMILY (REB 02–060), and START (REB 10–640). CHILD
669 was additionally approved by the respective Human Research Ethics Boards at McMaster

670 University, the Universities of Manitoba, Alberta, and British Columbia, and the Hospital for
671 Sick Children. Legal guardians of each participant provided written informed consent. Written
672 informed consent was obtained from the parent/guardian (participating mother) for each study
673 separately. We also have now obtained additional ethics board approval from HiREB (REB
674 16592) for using the data from the three cohorts together without additional consent from the
675 participants.

676 **Reference**

677

- 678 1. Stock SJ, Bauld L. Maternal smoking and preterm birth: An unresolved health challenge.
679 Vol. 17, PLoS Medicine. 2020.
- 680 2. Liu B, Xu G, Sun Y, Qiu X, Ryckman KK, Yu Y, et al. Maternal cigarette smoking before
681 and during pregnancy and the risk of preterm birth: A dose–response analysis of 25
682 million mother–infant pairs. PLoS Med. 2020;17(8).
- 683 3. Marufu TC, Ahankari A, Coleman T, Lewis S. Maternal smoking and the risk of still birth:
684 systematic review and meta-analysis. BMC Public Health. 2015;15(1).
- 685 4. Ventura SJ, Hamilton BE, Mathews TJ, Chandra A. Trends and variations in smoking
686 during pregnancy and low birth weight: Evidence from the birth certificate, 1990-2000.
687 Pediatrics. 2003;111(5 II).
- 688 5. U.S. Department of Health and Human Services. The Health Consequences of Smoking—
689 50 Years of Progress A Report of the Surgeon General. A Report of the Surgeon General.
690 2014.
- 691 6. Montgomery SM, Ekblom A. Smoking during pregnancy and diabetes mellitus in a British
692 longitudinal birth cohort. Br Med J. 2002;324(7328).
- 693 7. Toschke A, Koletzko B, Slikker W, Hermann M, von Kries R. Childhood obesity is
694 associated with maternal smoking in pregnancy. Eur J Pediatr. 2002;161(8).
- 695 8. Oken E, Levitan EB, Gillman MW. Maternal smoking during pregnancy and child
696 overweight: Systematic review and meta-analysis. Vol. 32, International Journal of
697 Obesity. 2008.
- 698 9. Philips EM, Santos S, Trasande L, Aurrekoetxea JJ, Barros H, von Berg A, et al. Changes
699 in parental smoking during pregnancy and risks of adverse birth outcomes and childhood
700 overweight in Europe and North America: An individual participant data meta-analysis of
701 229,000 singleton births. PLoS Med. 2020;17(8).
- 702 10. England LJ, Grauman A, Qian C, Wilkins DG, Schisterman EF, Yu KF, et al.
703 Misclassification of maternal smoking status and its effects on an epidemiologic study of
704 pregnancy outcomes. Nicotine and Tobacco Research. 2007;9(10).
- 705 11. Shipton D, Tappin DM, Vadiveloo T, Crossley JA, Aitken DA, Chalmers J. Reliability of
706 self reported smoking status by pregnant women for estimating smoking prevalence: A
707 retrospective, cross sectional study. BMJ (Online). 2009;339(7732).

- 708 12. Salmasi G, Grady R, Jones J, McDonald SD. Environmental tobacco smoke exposure and
709 perinatal outcomes: a systematic review and meta-analyses. Vol. 89, *Acta obstetrica et*
710 *gynecologica Scandinavica*. 2010.
- 711 13. Shenker NS, Ueland PM, Polidoro S, Van Veldhoven K, Ricceri F, Brown R, et al. DNA
712 methylation as a long-term biomarker of exposure to tobacco smoke. *Epidemiology*.
713 2013;24(5).
- 714 14. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al.
715 Epigenetic Signatures of Cigarette Smoking. *Circ Cardiovasc Genet*. 2016;9(5).
- 716 15. Guida F, Sandanger TM, Castagné R, Campanella G, Polidoro S, Palli D, et al. Dynamics
717 of smoking-induced genome-wide methylation changes with time since smoking cessation.
718 *Hum Mol Genet*. 2015;24(8).
- 719 16. Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwani FI, et al. Comparison
720 of smoking-related DNA methylation between newborns from prenatal exposure and
721 adults from personal smoking. *Epigenomics*. 2019;11(13).
- 722 17. Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco
723 Smoking Leads to Extensive Genome-Wide Changes in DNA Methylation. *PLoS One*.
724 2013 May 17;8(5).
- 725 18. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA
726 Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide
727 Consortium Meta-analysis. *Am J Hum Genet*. 2016;98(4).
- 728 19. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Hougaard DM, et al.
729 Variable DNA methylation in neonates mediates the association between prenatal
730 smoking and birth weight. *Philosophical Transactions of the Royal Society B: Biological*
731 *Sciences*. 2019;374(1770).
- 732 20. Akhbir L, Stringer R, Desai D, Mandhane PJ, Azad MB, Moraes TJ, et al. DNA
733 methylation changes in cord blood and the developmental origins of health and disease – a
734 systematic review and replication study. *BMC Genomics*. 2022;23(1).
- 735 21. Witt SH, Frank J, Gilles M, Lang M, Treutlein J, Streit F, et al. Impact on birth weight of
736 maternal smoking throughout pregnancy mediated by DNA methylation. *BMC Genomics*.
737 2018;19(1).
- 738 22. Küpers LK, Xu X, Jankipersadsing SA, Vaez A, La Bastide-van Gemert S, Scholtens S, et
739 al. DNA methylation mediates the effect of maternal smoking during pregnancy on
740 birthweight of the offspring. *Int J Epidemiol*. 2015;44(4).
- 741 23. Xu R, Hong X, Zhang B, Huang W, Hou W, Wang G, et al. DNA methylation mediates
742 the effect of maternal smoking on offspring birthweight: a birth cohort study of multi-
743 ethnic US mother–newborn pairs. *Clin Epigenetics*. 2021;13(1).
- 744 24. Cardenas A, Lutz SM, Everson TM, Perron P, Bouchard L, Hivert MF. Mediation by
745 Placental DNA Methylation of the Association of Prenatal Maternal Smoking and Birth
746 Weight. *Am J Epidemiol*. 2019;188(11).
- 747 25. Murray R, Kitaba N, Antoun E, Titcombe P, Barton S, Cooper C, et al. Influence of
748 maternal lifestyle and diet on perinatal DNA methylation signatures associated with
749 childhood arterial stiffness at 8 to 9 years. *Hypertension*. 2021;78(3).
- 750 26. Raynor P, Duley L, Small N, Tuffnell D, Wild C, Wright J, et al. Born in Bradford, a
751 cohort study of babies born in Bradford, and their parents: Protocol for the recruitment
752 phase. *BMC Public Health*. 2008;8.

- 753 27. Elliott HR, Burrows K, Min JL, Tillin T, Mason D, Wright J, et al. Characterisation of
754 ethnic differences in DNA methylation between UK-resident South Asians and Europeans.
755 Clin Epigenetics [Internet]. 2022 Dec 1 [cited 2023 Mar 9];14(1). Available from:
756 <https://pubmed.ncbi.nlm.nih.gov/36243740/>
- 757 28. Choquet H, Yin J, Jorgenson E. Cigarette smoking behaviors and the importance of
758 ethnicity and genetic ancestry. *Transl Psychiatry*. 2021;11(1).
- 759 29. Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. Differences in
760 smoking associated DNA methylation patterns in South Asians and Europeans. *Clin*
761 *Epigenetics*. 2014;6(1).
- 762 30. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: A robust
763 classifier to determine smoking status from DNA methylation data. *Epigenomics*.
764 2019;11(13).
- 765 31. Yousefi PD, Suderman M, Langdon R, Whitehurst O, Davey Smith G, Relton CL. DNA
766 methylation-based predictors of health: applications and statistical considerations. Vol. 23,
767 *Nature Reviews Genetics*. 2022.
- 768 32. Wright J, Small N, Raynor P, Tuffnell D, Bhopal R, Cameron N, et al. Cohort profile: The
769 born in bradford multi-ethnic family cohort study. *Int J Epidemiol*. 2013;42(4).
- 770 33. Reitsma MB, Flor LS, Mullany EC, Gupta V, Hay SI, Gakidou E. Spatial, temporal, and
771 demographic patterns in prevalence of smoking tobacco use and initiation among young
772 people in 204 countries and territories, 1990–2019. *Lancet Public Health*. 2021;6(7).
- 773 34. Morrison KM, Atkinson SA, Yusuf S, Bourgeois J, McDonald S, McQueen MJ, et al. The
774 Family Atherosclerosis Monitoring In earLY life (FAMILY) study. Rationale, design, and
775 baseline data of a study examining the early determinants of atherosclerosis. *Am Heart J*.
776 2009;158(4).
- 777 35. Anand SS, Vasudevan A, Gupta M, Morrison K, Kurpad A, Teo KK, et al. Rationale and
778 design of South Asian Birth Cohort (START): A Canada-India collaborative study. *BMC*
779 *Public Health*. 2013;13(1).
- 780 36. Brydon P, Smith T, Proffitt M, Gee H, Holder R, Dunne F. Pregnancy outcome in women
781 with type 2 diabetes mellitus needs to be addressed. *Int J Clin Pract*. 2000;54(7).
- 782 37. Farrar D, Fairley L, Santorelli G, Tuffnell D, Sheldon TA, Wright J, et al. Association
783 between hyperglycaemia and adverse perinatal outcomes in south Asian and white British
784 women: analysis of data from the Born in Bradford cohort. *Lancet Diabetes Endocrinol*
785 [Internet]. 2015 Oct 1 [cited 2023 Jun 8];3(10):795. Available from:
786 </pmc/articles/PMC4673084/>
- 787 38. Lange S, Probst C, Rehm J, Popova S. National, regional, and global prevalence of
788 smoking during pregnancy in the general population: a systematic review and meta-
789 analysis. *Lancet Glob Health*. 2018;6(7).
- 790 39. Markunas CA, Xu Z, Harlid S, Wade PA, Lie RT, Taylor JA, et al. Identification of DNA
791 Methylation Changes in Newborns Related to Maternal Smoking during Pregnancy.
792 *Environ Health Perspect*. 2014;122(10).
- 793 40. Richmond RC, Simpkin AJ, Woodward G, Gaunt TR, Lyttleton O, McArdle WL, et al.
794 Prenatal exposure to maternal smoking and offspring DNA methylation across the
795 lifecourse: Findings from the Avon Longitudinal Study of Parents and Children
796 (ALSPAC). *Hum Mol Genet*. 2015;24(8).
- 797 41. Rider CF, Carlsten C. Air pollution and DNA methylation: Effects of exposure in humans.
798 Vol. 11, *Clinical Epigenetics*. 2019.

- 799 42. Vogel CFA, Van Winkle LS, Esser C, Haarmann-Stemmann T. The aryl hydrocarbon
800 receptor as a target of environmental stressors – Implications for pollution mediated stress
801 and inflammatory responses. Vol. 34, Redox Biology. 2020.
- 802 43. Reynolds LM, Wan M, Ding J, Taylor JR, Lohman K, Su D, et al. DNA Methylation of
803 the Aryl Hydrocarbon Receptor Repressor Associations with Cigarette Smoking and
804 Subclinical Atherosclerosis. *Circ Cardiovasc Genet*. 2015;8(5).
- 805 44. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Vol. 84, Life Sciences.
806 2009.
- 807 45. Everson TM, Vives-Usano M, Seyve E, Cardenas A, Lacasaña M, Craig JM, et al.
808 Placental DNA methylation signatures of maternal smoking during pregnancy and
809 potential impacts on fetal growth. *Nat Commun*. 2021;12(1).
- 810 46. Moshhammer H, Hutter HP. Breast-feeding protects children from adverse effects of
811 environmental Tobacco smoke. *Int J Environ Res Public Health*. 2019;16(3).
- 812 47. de Souza RJ, Zulyniak MA, Desai D, Shaikh MR, Campbell NC, Lefebvre DL, et al.
813 Harmonization of food-frequency questionnaires and dietary pattern analysis in 4
814 ethnically diverse birth cohorts. *Journal of Nutrition*. 2016;146(11).
- 815 48. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA
816 methylation array with single CpG site resolution. *Genomics*. 2011;98(4).
- 817 49. Zhou W, Triche TJ, Laird PW, Shen H. SeSAMe: Reducing artifactual detection of DNA
818 methylation by Infinium BeadChips in genomic deletions. *Nucleic Acids Res*.
819 2018;46(20).
- 820 50. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al.
821 Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium
822 HumanMethylation450 microarray. *Epigenetics*. 2013;8(2).
- 823 51. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative
824 use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res*. 2017;45(4).
- 825 52. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical
826 evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome
827 DNA methylation profiling. *Genome Biol*. 2016;17(1).
- 828 53. Hillary RF, McCartney DL, McRae AF, Campbell A, Walker RM, Hayward C, et al.
829 Identification of influential probe types in epigenetic predictions of human traits:
830 implications for microarray design. *Clin Epigenetics*. 2022;14(1).
- 831 54. Gervin K, Salas LA, Bakulski KM, Van Zelm MC, Koestler DC, Wiencke JK, et al.
832 Systematic evaluation and validation of reference and library selection methods for
833 deconvolution of cord blood DNA methylation data. *Clin Epigenetics*. 2019;11(1).
- 834 55. R Core Team. R core team (2021). R: A language and environment for statistical
835 computing. R Foundation for Statistical Computing, Vienna, Austria. URL [http://www.R-](http://www.R-project.org)
836 [project.org](http://www.R-project.org). 2021.
- 837 56. Metzger BE. International Association of Diabetes and Pregnancy Study Groups
838 recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Vol.
839 33, *Diabetes Care*. 2010.
- 840 57. Anand SS, Razak F, Davis AD, Jacobs R, Vuksan V, Teo K, et al. Social disadvantage
841 and cardiovascular disease: Development of an index and analysis of age, sex, and
842 ethnicity effects. *Int J Epidemiol*. 2006;35(5).
- 843 58. Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized
844 regression on summary statistics. *Genet Epidemiol*. 2017;(February):469–80.

845

846

847